Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer
The major translational relevance of this study is to exploit new targets for the development of innovative and improved therapeutic strategies with NOA drugs, over combinations including target genes within the oncogene pathway, to overcome resistance to TKI therapies in patients with NSCLC who are oncogene-addicted.
Authors
- Francesca Iommelli (ORCID: https://orcid.org/0000-0002-5132-3593)
- Floriana Morgillo (ORCID: https://orcid.org/0000-0002-9167-323X)
- Concetta Tuccillo (ORCID: https://orcid.org/0000-0001-8713-2169)
- Virginia Tirino (ORCID: https://orcid.org/0000-0003-2731-5718)
- Rosanna Palumbo (ORCID: https://orcid.org/0000-0002-3858-4529)
- Anna Nardelli (ORCID: https://orcid.org/0000-0003-4215-6022)
- Vitale Del Vecchio (ORCID: https://orcid.org/0000-0002-7323-4444)
- Carminia M. Della Corte (ORCID: https://orcid.org/0000-0002-3396-8099)
- Cristina Terlizzi (ORCID: https://orcid.org/0000-0001-5422-4737)
- Federica Papaccio (ORCID: https://orcid.org/0000-0002-0302-8696)
- Roberta Buono (ORCID: https://orcid.org/0000-0002-0033-5375)
- Viviana De Rosa (ORCID: https://orcid.org/0000-0002-0430-5608)
- Daniela Omodei (ORCID: https://orcid.org/0000-0001-8710-2971)
- Annalisa Ariano
- Caterina De Rosa (ORCID: https://orcid.org/0000-0001-6540-0708)
- Luisa Amato (ORCID: https://orcid.org/0009-0005-6511-8071)
- S. Capaldo
- Camilla Carmela Tufano
Institutions
- University of Salerno (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona (IT)
- Institute of Biostructure and Bioimaging (IT)
- National Research Council (IT)
- Link Campus University (IT)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-25
- DOI
- https://doi.org/10.3390/cancers16233941
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Regeneron Pharmaceuticals
- Associazione Italiana per la Ricerca sul Cancro
- European Society for Medical Oncology
- Fondazione Italiana per la Ricerca sul Cancro
- PharmaMar